Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEWTON-CABG
2021-002343-30Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in hyperlipidemia and coronary arteriosclerosis comparing Repatha with Placebo (2 arms). Primary endpoint: Saphenous vein graft disease rate. Started Jul 2021; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiacoronary arteriosclerosis
Beyond the preview
Go deeper on 2021-002343-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002343-30.